Telomir Pharmaceuticals reports favorable GLP safety results for Telomir-1; IND submission targeted Q1 2026

Telomir Pharmaceuticals, Inc.

No treatment-related adverse or dose-limiting toxicities observed across cardiovascular, respiratory, phototoxicity, and repeat-dose safety studies in rats and dogs.
Telomir-1 well tolerated with consistent systemic exposure; no changes in blood pressure, heart rate, ECG, or body temperature in dogs.
Final quality assurance review ongoing; no findings preclude advancement into first-in-human studies.
Ongoing preclinical studies in triple-negative breast cancer and other age-related diseases; targeting IND submission Q1 2026 and first-in-human H1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.